Beasley Allen has one of the largest and most technologically advanced Mass Torts practices in the country. The Mass Torts division represents numerous people in claims against companies that manufacture and/or market defective pharmaceuticals and/or medical devices. The resources devoted to this division allow the firm to competently and conscientiously handle any group of cases, no matter how large, along with particular catastrophic injury cases.
Our firm was recently involved in one of the greatest victories in Mass Torts history, against drug manufacturer Merck regarding the drug Vioxx. After more than five years of hard-fought and difficult litigation, Merck agreed to pay $4.85 billion, the largest pharmaceutical settlement in U.S. history, to resolve certain Vioxx-related claims involving plaintiffs who suffered a heart attack, including sudden cardiac death, or a stroke.
It took nine days for Dave Maeder to go through withdrawal from the medication patch he was prescribed to treat nausea caused by a brain injury. Nine days of tortuous symptoms like severe nausea and vomiting, insomnia and sleepiness, restlessness and paranoia. It was like he was withdrawing from heroin. But the medicine patch Dave was on – scopolamine – is not a controlled substance. It does not give users a euphoric feeling. It’s not sought after as a recreational drug at all. In fact, the safety label only suggests that the medication “may result in withdrawal symptoms” in the ... Read More
Johnson & Johnson and its subsidiary Janssen Pharmaceuticals face more than 15,000 lawsuits over alleged disfiguring side effects caused by its antipsychotic drug Risperdal. The last case to be tried resulted in a $70 million verdict in favor of a young Tennessee boy. The next scheduled trial, which involved a New York boy who claimed he suffered serious Risperdal side effects, ended with a confidential settlement agreement early this year. Could that be a sign that the pharmaceutical giant is considering settling more cases? J&J says it is taking each case one-by-one to decide whether a settlement is in order. ... Read More
Aurobindo Pharma Limited issued a recall for a generic version of the injectable heartburn treatment Protonix because some vials appeared to be discolored with a possible contaminant. Pantoprazole sodium is the active ingredient in Protonix. It is a class of acid-reducing drugs called proton pump inhibitors, or PPIs, which work by blocking the production of acid in the stomach. The medication is intended to be used short-term (7 to 10 days) in adult patients to treat esophageal reflux disease (GERD) and a history of erosive esophagitis. The recall affects 29,800 vials of pantoprazole sodium for injection, 40mg per vial, single dose. ... Read More
The Kashmir Monitor encourages readers who are experiencing hair loss to make themselves aware of the various causes. “The key to finding a solution to thinning hair or baldness is determining the root of the problem and seeking treatment accordingly,” the article states. The article lists 10 different possible reasons that a person might be suffering from hair loss, and treatments when applicable. Some of the causes were purely physical, such as thyroid disorders and nutrient deficiencies, in which getting your hormones or your diet back in balance will allow your hair to start growing again. The article warns readers ... Read More
Pharmaceutical company Dr. Reddy’s Laboratories is recalling a generic version of the antipsychotic Zyprexa, known chemically as olanzapine, because the drug failed impurity and degradation specification testing. “Due to out-of-specification results for the Related Substance Compound C (Impurity 6 – N-Oxide at the 18 month stability station,” the recall noticed stated. The recall is classified as a Class III, which is a less serious type of recall reserved for products in which use of exposure is not likely to cause adverse health consequences. Olanzapine was approved by the Food and Drug Administration (FDA) in 2009 under the brand name Zyprexa. It ... Read More
Researchers from the University of British Columbia (UBC) have conducted an initial trial of Viagra as a treatment for early intrauterine growth restriction, according to Counsel and Heal. In this rare condition, the placenta does not supply enough nutrients to the fetus which results in premature delivery or stillbirth. Treatment options for this condition are limited. Scientists wondered if sildenafil, the active ingredient in Viagra, which works by increasing blood flow, might be able to increase the flow of nutrients to the fetus. According to Dr. Kenneth Lim of B.C. Women’s Hospital, the results of the small initial study were promising ... Read More
The Food and Drug Administration (FDA) vowed that it will deliver warnings regarding recalled medical devices to the public in a more timely manner in 2017. The FDA defines a medical device recall as a correction or removal action to address a problem with a device that violates FDA law. Recalls occur when a medical device is defective, when it could be a risk to health, or when it is both defective and a risk to health. When the FDA learns of a company’s recall or removal action regarding a medical device, the agency reviews the strategy the company poses ... Read More
The first bellwether trial in the massive multidistrict litigation (MDL) involving bleeding risks with the blood thinner Xarelto was scheduled to begin this month in the Eastern District of Louisiana, but the National Basketball Association (NBA) All Star game occurring in New Orleans at the same time pushed U.S. District Judge Eldon Fallon to delay trial until March. The Xarelto MDL under Judge Fallon has swelled to nearly 14,000 lawsuits since the it was first consolidated in December 2014. Last summer, Judge Fallon had scheduled the first cases to be tried, with the first to be tried in February. But the ... Read More
A bill introduced in the U.S. House of Representatives will give the Food and Drug Administration (FDA) the authority to require manufacturers of over-the-counter (OTC) medicines to stop marketing unsafe products. The Recall Unsafe Drugs Act, introduced by Rep. Rosa DeLauro (D-CT), would give the FDA the authority to wield its power over medicines and homeopathic products, closing up a loophole that currently allows companies to refuse the FDA’s request that they remove products from the market if they are deemed unsafe. For example, last month the FDA asked Standard Homeopathic Company to recall its Hyland’s homeopathic teething gels and tablets ... Read More
Dietary supplement maker Cili Minerals has agreed to stop manufacturing and selling untested products that promised to treat serious conditions including heart disease, multiple sclerosis, and cancer. The agreement, penned by the Justice Department and the U.S. Attorney in Lafayette, Louisiana, also requires Cili Minerals to recall and destroy all products it made and distributed since June 1, 2014. Lafayette, Louisiana-based Cili Minerals is owned by Anton S. Botha, and operated under names including Pick and Pay Inc., and Pick and Pay Hyper Inc. Its products were sold under various names including ProLith, Germanium and CilZinCo. The company’s products were ... Read More